The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia
- PMID: 23001040
- PMCID: PMC3676480
- DOI: 10.1038/onc.2012.411
The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia
Abstract
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and remains incurable with conventional chemotherapy treatment approaches. CLL as a disease entity is defined by a relatively parsimonious set of diagnostic criteria and therefore likely constitutes an umbrella term for multiple related illnesses. Of the enduring fundamental biological processes that affect the biology and clinical behavior of CLL, few are as central to the pathogenesis of CLL as recurrent acquired genomic copy number aberrations (aCNA) and recurrent gene mutations. Here, a state-of-the-art overview of the pathological anatomy of the CLL genome is presented, including detailed descriptions of the anatomy of aCNA and gene mutations. Data from SNP array profiling and large-scale sequencing of large CLL cohorts, as well as stimulated karyotyping, are discussed. This review is organized by discussions of the anatomy, underlying pathomechanisms and clinical significance of individual genomic lesions and recurrent gene mutations. Finally, gaps in knowledge regarding the biological and clinical effects of recurrent genomic aberrations or gene mutations on CLL are outlined to provide critical stimuli for future research.
Figures



Similar articles
-
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.Clin Cancer Res. 2013 Jun 1;19(11):2893-904. doi: 10.1158/1078-0432.CCR-13-0138. Epub 2013 Apr 25. Clin Cancer Res. 2013. PMID: 23620403 Free PMC article.
-
Acquired genomic copy number aberrations in CLL.Adv Exp Med Biol. 2013;792:47-86. doi: 10.1007/978-1-4614-8051-8_3. Adv Exp Med Biol. 2013. PMID: 24014292 Review.
-
Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.Haematologica. 2011 Aug;96(8):1161-9. doi: 10.3324/haematol.2010.039768. Epub 2011 May 5. Haematologica. 2011. PMID: 21546498 Free PMC article.
-
Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays.Blood. 2007 Feb 1;109(3):1202-10. doi: 10.1182/blood-2006-07-034256. Epub 2006 Oct 19. Blood. 2007. PMID: 17053054
-
Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: An evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia.Cancer Genet. 2018 Dec;228-229:236-250. doi: 10.1016/j.cancergen.2018.07.004. Epub 2018 Oct 16. Cancer Genet. 2018. PMID: 30554732 Review.
Cited by
-
Genome-wide analysis of microRNA and mRNA expression signatures in cancer.Acta Pharmacol Sin. 2015 Oct;36(10):1200-11. doi: 10.1038/aps.2015.67. Epub 2015 Aug 24. Acta Pharmacol Sin. 2015. PMID: 26299954 Free PMC article. Review.
-
Aberrant BCAT1 expression augments MTOR activity and accelerates disease progression in chronic lymphocytic leukemia.Leukemia. 2025 Jan;39(1):112-121. doi: 10.1038/s41375-024-02448-8. Epub 2024 Oct 25. Leukemia. 2025. PMID: 39455853 Free PMC article.
-
Copy neutral loss of heterozygosity in 20q in chronic lymphocytic leukemia/small lymphocytic lymphoma.Cancer Genet. 2014 Mar;207(3):98-102. doi: 10.1016/j.cancergen.2014.02.005. Epub 2014 Feb 15. Cancer Genet. 2014. PMID: 24704113 Free PMC article.
-
Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia.Genes Chromosomes Cancer. 2015 Nov;54(11):668-80. doi: 10.1002/gcc.22277. Epub 2015 Aug 25. Genes Chromosomes Cancer. 2015. PMID: 26305789 Free PMC article.
-
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.Clin Cancer Res. 2017 Feb 15;23(4):1049-1059. doi: 10.1158/1078-0432.CCR-15-2921. Epub 2016 Aug 17. Clin Cancer Res. 2017. PMID: 27535981 Free PMC article.
References
-
- Shanafelt TD, Hanson C, Dewald GW, Witzig TE, LaPlant B, Abrahamzon J, et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol. 2008;26:e5–e6. - PMC - PubMed
-
- Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916. - PubMed
-
- Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the National Cancer Research Institute CLL206 Trial. J Clin Oncol. 2012;30:1647–1655. - PubMed
-
- Spaner DE. Oral high-dose glucocorticoids and ofatumumab in fludarabine-resistant chronic lymphocytic leukemia. Leukemia. 2012;26:1144–1145. - PubMed
-
- Stilgenbauer S, Zenz T, Winkler D, Buhler A, Schlenk RF, Groner S, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994–4001. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources